“…Of these, 432 were excluded for the following reasons: commentaries or reviews ( n = 71); neurodevelopment, cognitive, or behavioral outcomes ( n = 72); other unrelated health outcomes ( n = 86); studies of hemp oil, synthetic or endogenous cannabinoids, or the endocannabinoid system ( n = 36); polysubstance use or drugs other than cannabis ( n = 24); characteristics or reasons for cannabis use ( n = 43); prevalence studies ( n = 18); biomarker studies ( n = 16); cessation or prevention studies ( n = 9); health policy analyses ( n = 3); effects of pre-conception cannabis use ( n = 3); abstracts or reports presenting insufficient data ( n = 2); and papers focused entirely on unrelated exposures and outcomes ( n = 50). Thus, 47 epidemiologic studies [ 3 , 4 , 14 – 18 , 19 ••, 20 – 28 , 29 •, 30 – 33 , 34 ••, 35 – 58 ] and 12 animal models [ 59 , 60 ••, 61 , 62 , 63 ••, 64 , 65 ••, 66 •, 67 – 70 ] presenting original data met the inclusion criteria for this review.…”